YDYoung Woo Do

Young Woo Do

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Young Woo Do has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of BTRC rs10883617 with Survival Outcomes in Surgically Resected Non-Small Cell Lung Cancer

    by Seongwon Shin, Chi Young Jung, Mi Jeong Hong, Jang Hyuck Lee, Won Kee Lee, Ji Eun Park, Yong Hoon Lee, Hyewon Seo, Jaehee Lee, Shin Yup Lee, et al.

    Background/Objectives: Genetic variation in components of the ubiquitin–proteasome system may contribute to cancer progression and clinical outcomes. This study investigated whether potentially functional variants in E3 ubiquitin ligase-related genes are associated with survival outcomes after surgical resection of non-small cell lung cancer (NSCLC). Methods: The study included 744 Korean patients with stage I–IIIA NSCLC, divided into discovery and validation cohorts. Fifty-one potentially functional single-nucleotide polymorphisms in E3 ubiquitin ligase-related genes were evaluated for associations with overall survival (OS) and disease-free survival (DFS). Results: Among the polymorphisms examined, BTRC rs10883617 T>C was significantly associated with DFS in the validation cohort, whereas the association with OS showed a concordant trend but did not reach statistical significance. In the combined cohort, carriers of at least one C allele had significantly better OS (HR = 0.55, 95% CI = 0.34–0.90, p = 0.02) and DFS (HR = 0.64, 95% CI = 0.46–0.89, p = 0.01) than patients with the TT genotype. The C allele demonstrated significantly lower promoter activity than the T allele in A549 and H1299 lung cancer cell lines (both p < 0.01). BTRC mRNA expression was significantly higher in tumor tissues than in paired non-neoplastic tissues (p < 0.001), but did not differ by genotype. Conclusions: Collectively, BTRC rs10883617 T>C was associated with favorable survival outcomes and allele-specific promoter activity in surgically resected NSCLC. However, its effect on endogenous BTRC expression remains unconfirmed in this patient population. Independent external validation and further mechanistic studies are warranted.

  • Open Access

    Nitroxoline Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Suppressing STAT3-AKT-MTOR Survival Signaling

    by Eun-Young Gong, Hye Won Lee, Hyunseung Oh, Jae-Ho Lee, Sang Jun Byun, Jeong-Woo Hwang, Sung Uk Bae, Hyowon Hong, Young Woo Do

    Radiotherapy is the central component in non-small cell lung cancer (NSCLC) treatment. Nonetheless, its therapeutic effectiveness is frequently compromised by adaptive engagement of prosurvival signaling pathways that foster radioresistance. STAT3 functions as the central signaling node that orchestrates cellular survival responses following radiation exposure. This study investigated whether nitroxoline, a clinically approved antimicrobial agent with STAT3-inhibitory activity, enhances radiosensitivity of NSCLC cells and how these effects are mechanistically regulated. We examined the combined effects of nitroxoline and radiation on cell viability and associated signaling pathways in NSCLC cells. Nitroxoline significantly enhanced radiation-induced cytotoxicity and suppressed clonogenic survival compared with radiation alone. Irradiation increased STAT3, AKT, and mTOR phosphorylation, whereas nitroxoline effectively suppressed the basal and radiation-induced activation of these pathways. The combination treatment markedly augmented radiation-induced apoptosis, as demonstrated by increased p53 expression and enhanced PARP and caspase-3 cleavage. Additionally, nitroxoline amplified radiation-induced DNA damage signaling, resulting in pronounced γ-H2AX and DNA-PKcs accumulation. Nitroxoline enhanced NSCLC cell radiosensitivity by suppressing STAT3–AKT–mTOR survival signaling, promoting apoptosis, and amplifying radiation-induced DNA damage, indicating the potential of repurposing nitroxoline as a radiosensitizer to improve radiotherapy outcomes in patients with NSCLC.